22:01 , Jul 19, 2019 |  BioCentury  |  Product Development

Gilead’s $5.1B Galapagos deal threads the needle between M&A and licensing

The structure of Gilead’s partnership with Galapagos gives the U.S. biotech access to all of Galapagos’ programs, without the brain drain that followed its acquisition of Kite. Human capital was the driver behind Gilead Sciences...
19:42 , Jul 19, 2019 |  BC Extra  |  Company News

Gilead picks up dropped Novartis antiviral programs

Gilead in-licensed from Novartis three preclinical antiviral programs that will help build out its preclinical pipeline in indications outside of its historical focus. Under the deal, Gilead Sciences Inc. (NASDAQ:GILD) receives exclusive, worldwide rights from...
23:45 , Jul 18, 2019 |  BC Extra  |  Financial News

Kronos parlays diverse pipeline into $105M series A

The speed at which Kronos assembled a broad small molecule platform against hard-to-target hormone receptors, transcription factors and E3 ligases enabled it to raise a $105 million A round led by seed investors Vida Ventures...
19:17 , Jul 17, 2019 |  BC Extra  |  Company News

Gilead CSO McHutchison, two others, out as O’Day reshapes his team

With the departures of CSO John McHutchison, Chief Patient Officer Gregg Alton and EVP of Human Resources Katie Watson announced Wednesday, Daniel O'Day will be left with less than half of the 10-person senior management...
15:06 , Jul 15, 2019 |  BC Extra  |  Company News

Galapagos maintains independence, adds R&D firepower with $5.1 billion megadeal with Gilead

A partnership with Gilead allows Galapagos to nearly double the size of its clinical pipeline, with the potential to add new technology platforms via BD, and ensures its independence into the next decade. Under the...
23:17 , Jul 12, 2019 |  BC Extra  |  Financial News

HitGen joins growing Shanghai IPO queue

The Shanghai Stock Exchange accepted an application from HitGen this week to list on its new science and technology innovation board. The small molecule discovery company proposed to sell at least 40 million shares and...
20:45 , Jul 11, 2019 |  BC Extra  |  Company News

Management tracks: President of Lilly BioMedicines steps down to lead Kite; plus Alnylam, GSK, and more

Christi Shaw, SVP and president of Lilly BioMedicines at Eli Lilly and Co. (NYSE:LLY), will step down at the end of August to serve as CEO of the Kite Pharma unit of Gilead Sciences Inc....
23:53 , Jul 10, 2019 |  BC Extra  |  Politics & Policy

CMS’s new CKD payment models could be mixed bag for drug companies

A set of five different payment models announced by the Centers for Medicare & Medicaid Services for patients with chronic kidney disease or end-stage renal disease could be a boon for companies that have taken...
22:39 , Jul 9, 2019 |  BC Extra  |  Company News

July 9 Company Quick Takes: Celgene, Nimbus expand deal; plus Gilead-Lyndra, Darzalex and more

Celgene gets option for Nimbus' HPK1 program  Celgene Corp. (NASDAQ:CELG) expanded its partnership with Nimbus Therapeutics LLC (Cambridge, Mass.) to include an option for the latter's HPK1 inhibitor to treat cancer, which Celgene can exercise...
22:28 , Jul 2, 2019 |  BC Extra  |  Company News

July 2 Company Quick Takes: Gilead's Truvada REMS removed; plus UC, Amicus/Paragon and Iovance

FDA removes REMS for Truvada  FDA said it is eliminating the REMS for Truvada emtricitabine/tenofovir from Gilead Sciences Inc. (NASDAQ:GILD) and its four generics approved for pre-exposure prophylaxis (PrEP), which required manufacturers to provide educational...